Literature DB >> 23085462

Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity.

Jamie Jennings-Gee1, Timothy S Pardee, William H Gmeiner.   

Abstract

Previous studies have indicated that 5-Fluoro-2'-deoxyuridine-5'-O-monophosphate 10mer (FdUMP[10]) displays strong antileukemic activity through the dual targeting of thymidylate synthase (TS) and DNA topoisomerase 1 (Top1). The present studies were undertaken to clarify the relationship between the induction of a thymineless state and the formation of Top1 cleavage complexes (Top1CC) for inducing cell death and to clarify the role of DNA replication for induction of lethal DNA double-strand breaks (DSBs) in FdUMP[10]-treated acute myeloid leukemia (AML) cells. Human promyelocytic (HL60) and AML (KG1a, Molm13, THP-1) cells were synchronized by serum starvation and treated with FdUMP[10] with thymidine (Thy) rescue. Cells were assayed for TS inhibition, DNA DSBs, Top1CC, and apoptosis to clarify the interrelationship of TS inhibition and Top1CC for cell death. FdUMP[10] induced a thymineless state in AML cells and exogenous Thy administered within the first 18 hours of treatment rescued FdUMP[10]-induced Top1CC formation, γH2AX phosphorylation, and apoptosis induction. Exogenous Thy was not effective after cells had committed to mitosis and undergone cell division in the presence of FdUMP[10]. FdUMP[10] treatment resulted in Chk1 activation, and Chk1 inhibition enhanced FdUMP[10]-induced DNA damage and apoptosis. Jnk-signaling was required for FdUMP[10]-induced apoptosis in promyelocytic HL60 cells and in THP1 cells, but was antiapoptotic in Molm13 and to a lesser extent KG1a AML cells. The results are consistent with FdUMP[10] inducing a thymineless state, leading to misincorporation of FdU into genomic DNA of proliferating cells. Top1CC form in cells upon re-entry into S-phase, resulting in DNA double-strand breaks, and initiating apoptotic signaling that can be either muted or enhanced by Jnk-signaling depending on cell type.
Copyright © 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23085462      PMCID: PMC3660094          DOI: 10.1016/j.exphem.2012.10.007

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  35 in total

1.  S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.

Authors:  William A Cliby; Kriste A Lewis; Kia K Lilly; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2001-11-07       Impact factor: 5.157

2.  A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.

Authors:  Zhi-Yong Liao; Olivier Sordet; Hong-Liang Zhang; Glenda Kohlhagen; Smitha Antony; William H Gmeiner; Yves Pommier
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

3.  Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity.

Authors:  Timothy S Pardee; Evan Gomes; Jamie Jennings-Gee; David Caudell; William H Gmeiner
Journal:  Blood       Date:  2012-02-23       Impact factor: 22.113

Review 4.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks.

Authors:  Chao-Po Lin; Yi Ban; Yi Lisa Lyu; Leroy F Liu
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

6.  The effect of 5-fluorouracil on erythropoiesis.

Authors:  I N Rich
Journal:  Blood       Date:  1991-03-15       Impact factor: 22.113

7.  Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

Authors:  William H Gmeiner; William C Reinhold; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2010-12       Impact factor: 6.261

8.  Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Authors:  Jeffrey Hrkach; Daniel Von Hoff; Mir Mukkaram Ali; Elizaveta Andrianova; Jason Auer; Tarikh Campbell; David De Witt; Michael Figa; Maria Figueiredo; Allen Horhota; Susan Low; Kevin McDonnell; Erick Peeke; Beadle Retnarajan; Abhimanyu Sabnis; Edward Schnipper; Jeffrey J Song; Young Ho Song; Jason Summa; Douglas Tompsett; Greg Troiano; Tina Van Geen Hoven; Jim Wright; Patricia LoRusso; Philip W Kantoff; Neil H Bander; Christopher Sweeney; Omid C Farokhzad; Robert Langer; Stephen Zale
Journal:  Sci Transl Med       Date:  2012-04-04       Impact factor: 17.956

9.  The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs.

Authors:  William H Gmeiner; Freddie Salsbury; Chris M Olsen; Luis A Marky
Journal:  J Nucleic Acids       Date:  2011-08-28

10.  Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.

Authors:  E J Morris; H M Geller
Journal:  J Cell Biol       Date:  1996-08       Impact factor: 10.539

View more
  9 in total

Review 1.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

2.  The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.

Authors:  William H Gmeiner; Olcay Boyacioglu; Christopher H Stuart; Jamie Jennings-Gee; K C Balaji
Journal:  Prostate       Date:  2014-11-18       Impact factor: 4.104

3.  F10 Inhibits Growth of PC3 Xenografts and Enhances the Effects of Radiation Therapy.

Authors:  William H Gmeiner; Mark C Willingham; J Daniel Bourland; Heather C Hatcher; Thomas L Smith; Ralph B D'Agostino; William Blackstock
Journal:  J Clin Oncol Res       Date:  2014 Jul-Aug

4.  Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.

Authors:  William H Gmeiner; Jamie Jennings-Gee; Christopher H Stuart; Timothy S Pardee
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

5.  AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition.

Authors:  William H Gmeiner; Jonathan R Brody; Alex O Haber; Aditi Jain; Chinnadurai Mani; Avinoam Nevler; Lebaron C Agostini; Talia Golan; Komaraiah Palle; Charles J Yeo
Journal:  Mol Cancer Res       Date:  2021-02-16       Impact factor: 6.333

6.  Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.

Authors:  Chinnadurai Mani; Sachin Pai; Cinta Maria Papke; Komaraiah Palle; William H Gmeiner
Journal:  Neoplasia       Date:  2018-11-12       Impact factor: 5.715

7.  Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.

Authors:  Anthony Dominijanni; William H Gmeiner
Journal:  Cancer Drug Resist       Date:  2018-03-19

8.  Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.

Authors:  Anna Aviñó; Anna Clua; Maria José Bleda; Ramon Eritja; Carme Fàbrega
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

9.  The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.

Authors:  Timothy S Pardee; Kristin Stadelman; Jamie Jennings-Gee; David L Caudell; William H Gmeiner
Journal:  Oncotarget       Date:  2014-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.